Use Case II : Imaging Biomarkers and New Trends for Integrated Glioblastoma Management

Use Case II : Imaging Biomarkers and New Trends for Integrated Glioblastoma Management

© Springer International Publishing Switzerland 2017. Glioblastoma (GB) implies a devastating prognosis with an average survival of 14-16 months using the current standard of care treatment [1]. GB is the most frequent malignant tumour originating from the brain parenchyma, and it is characterised b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Fuster-Garcia, E, Garcia-Gomez, J.M, De Angelis, E, Sraum, A, Molnar, A, Van Huffel, Sabine, Stamatakos, G
Format: Buchkapitel
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:© Springer International Publishing Switzerland 2017. Glioblastoma (GB) implies a devastating prognosis with an average survival of 14-16 months using the current standard of care treatment [1]. GB is the most frequent malignant tumour originating from the brain parenchyma, and it is characterised by a marked intratumoural heterogeneity, proneness to infiltrate throughout the brain parenchyma, robust angiogenesis and necrosis as well as intense resistance to apoptosis and genomic instability.